Skip to main content
倍益康 logo

倍益康 — Investor Relations & Filings

Ticker · 920199 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 360 across all filing types
Latest filing 2023-01-30 Declaration of Voting R…
Country CN China
Listing Beijing Stock Exchange 920199

About 倍益康

https://www.qlbeoka.com/

Beiyikang focuses on the research, development, and manufacturing of rehabilitation and physical therapy equipment. The company integrates professional medical technology with consumer-oriented health solutions. Its product lineup features percussive massage devices, oxygen concentrators, blood pressure monitors, and specialized physical therapy instruments for pain relief and muscle recovery. By utilizing advanced manufacturing processes and technological innovation, Beiyikang delivers products for sports recovery, clinical rehabilitation, and personal health management. The company prioritizes the incorporation of smart technology into its hardware to improve therapeutic outcomes and user experience across its range of recovery and wellness devices.

Recent filings

Filing Released Lang Actions
2023年第一次临时股东大会会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a resolution announcement for the "2023 First Extraordinary General Meeting of Shareholders" of Sichuan Qianli Beiyikang Medical Technology Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and legal compliance statements. The content focuses on the outcomes of shareholder votes on various proposals, including stock price stabilization, share repurchase plans, authorization for the board to handle repurchase matters, use of idle funds for low-risk financial products, and amendments to information disclosure management. There is no financial data or detailed report content, but rather official voting results and resolutions from a shareholders meeting. This matches the definition of "Declaration of Voting Results & Voting Rights Announcements (DVA)" which covers official results from shareholder votes at any general meeting. The document length is 3395 characters, which is consistent with a detailed voting results announcement rather than a full report or presentation.
2023-01-30 Chinese
关于延长公司股东股份锁定期的公告（更正后）
Regulatory Filings Classification · 95% confidence The document is an official announcement from Sichuan Qianli Beiyikang Medical Technology Co., Ltd. regarding the extension of the lock-up period for shares held by major shareholders, directors, supervisors, and senior management. It details commitments and restrictions on share sales, lock-up periods, and the automatic extension of these periods based on stock price performance. The document references regulatory approvals and stock exchange listings but does not contain financial statements or earnings data. It is a regulatory announcement about shareholding restrictions and lock-up extensions rather than a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS). The document length is 4021 characters, which is relatively short and consistent with an announcement rather than a full report.
2023-01-29 Chinese
关于延长公司股东股份锁定期的公告(更正公告)
Regulatory Filings Classification · 95% confidence The document is a correction announcement regarding the extension of the lock-up period for shareholders' shares. It details specific shareholders, their locked shares, and the revised lock-up expiration dates. The content is focused on shareholding restrictions and corrections to a previous announcement. It does not contain financial statements, earnings data, or management discussion. It is not a full report but a regulatory announcement correcting prior information about share lock-up periods. Therefore, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2023-01-29 Chinese
前十大股东和前十大无限售条件股东情况公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement from Sichuan Qianli Beiyikang Medical Technology Co., Ltd. disclosing the top ten shareholders and top ten unrestricted shareholders as of January 18, 2023. It references a share repurchase plan that was approved by the board and is pending shareholder approval. The content focuses on shareholder holdings and share repurchase plans, which aligns with disclosures related to shareholding notifications or capital changes. The document is not a full financial report, earnings release, or management discussion. It is not a proxy solicitation or voting result announcement. Given the detailed shareholder information and the context of a share repurchase plan, the most appropriate classification is Major Shareholding Notification (MRQ). The document length is short and it is a direct announcement, not a report publication or certification. Therefore, the classification is MRQ with high confidence.
2023-01-29 Chinese
回购股份方案公告(更正公告)
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement regarding a correction to a previously disclosed share repurchase (buyback) plan by the company. It includes specifics about the number of shares to be repurchased, funding sources, impact on shareholding structure, financial analysis related to the buyback, and risks associated with the repurchase plan. The content focuses on the company's share repurchase activities and related disclosures rather than financial results, management changes, or other report types. The document length is over 5,000 characters and contains substantive details about the repurchase plan, not just a brief announcement or a link to a report. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers share repurchase announcements and related updates.
2023-01-11 Chinese
回购股份方案公告（更正后）
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement regarding a company's share repurchase plan, including the purpose, method, price, quantity, funding source, implementation period, and impact analysis. It discusses the board's approval, shareholder authorization, and regulatory compliance related to the share buyback. The content focuses on the company's capital structure changes through repurchasing its own shares, which aligns with the definition of a Transaction in Own Shares (POS). It is not a financial report, earnings release, or regulatory filing but a specific announcement about share repurchase activities.
2023-01-11 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.